Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

"Both studies demonstrated that Vectibix administered with chemotherapy significantly improved progression-free survival in patients with wild-type KRAS mCRC," said Marc Peeters, M.D., Ph.D., Professor of Oncology, Antwerp University Hospital and '181' trial lead investigator and study author. "The adverse event profiles in both trials were as expected for an anti-EGFR antibody treatment used in combination with these types of chemotherapy regimens. Additionally, these data reinforce that KRAS status should be known when choosing treatment strategies."

PRIME '203' Results in First-Line mCRC Demonstrate Vectibix Combined with Chemotherapy (FOLFOX) Helped Patients with Wild-type KRAS mCRC Live Longer Without their Disease Worsening (Progression-Free Survival or PFS)

  • The addition of Vectibix to FOLFOX (an oxaliplatin-based chemotherapy) significantly improved PFS (median 9.6 months for Vectibix plus FOLFOX versus 8.0 months for patients treated with FOLFOX alone, hazard ratio 0.80; 95 percent CI: 0.66-0.97; p=0.02) in the first-line treatment of patients with wild-type KRAS mCRC.  
  • Although numerically greater (23.9 months versus 19.7 months, hazard ratio 0.83; 95 percent CI: 0.67-1.02), the improvement in overall survival (OS) (secondary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.072) in the same patient population.
  • Importantly, in patients with tumors harb
    '/>"/>

  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
    2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
    3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
    4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
    5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
    7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
    8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
    9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
    10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
    11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters ... a high-end machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or ... design that even NIST used them for their SRM-2031 series going back for many ...
    (Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... highly-regarded by Fortune 500 companies and professional service industries alike-- typically known for ... make clients laugh, honor a good cause and break from their day jobs. ...
    (Date:7/3/2015)... Forskere kan søke ... Science", som finner sted i ... på  http://www.openinnovationinscience.at , og søknadsperioden varer frem ... to største utfordringene innen helsevitenskapen er mangelen ... og kompleksiteten av nåværende forskningsresultater, i følge ...
    (Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... the cuvette they needed. As expected, this was a daunting and tiring process looking ... because they were not able to navigate the complex catalog structure. , Now thanks to ...
    Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2
    ... the Cost of Genome Analysis to $100 In ... Routine Medical Care-PHILADELPHIA, Feb. 24 BioNanomatrix, Inc., ... analysis platforms for biomedical research, molecular diagnostics and ... genome analysis technology, along with founder and chief ...
    ... Gene Network Sciences, Inc. (GNS) today announced that it ... Officer of Stromedix, Inc. and former Executive Vice President ... Directors. Dr. Gilman has been Founder and Chief ... was previously Executive Vice President, Research at Biogen Idec. ...
    ... PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense ... threats, announced today that results from a Phase ... for Valortim(R) were presented at the 7th Annual ... held in Baltimore, MD, February 22-25, 2009. David ...
    Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Gene Network Sciences Announces Michael Gilman as Board Member 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 3PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 4PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 5PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 6PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 7
    (Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
    (Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
    (Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
    Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
    ... the leading cause of blindness in western society, say experts ... a new eye instrument, they have launched a study to ... strength could also explain why the 77-year-old sailor has no ... sweetcorn, kale and broccoli are rich in a chemical called ...
    ... virtually any other type of therapy, has given rise ... also great concerns regarding health risks. Since the Deutsche ... in 1995, this field of research has developed enormously. ... as well as the risks of gene therapy. The ...
    ... to accurately distinguish benign from malignant breast lesions. ... and harmless lesions in nearly all of the ... the annual meeting of the Radiological Society of ... imaging has been found to have high specificity,?said ...
    Cached Biology News:Why Popeye only has eyes for spinach 2Development of gene therapy 2Elasticity imaging identifies cancers and reduces breast biopsies 2
    ... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
    Request Info...
    ...
    ... target blotted protein on PVDF membrane or ... The N-terminal sequence of proteins (5-20 residues) ... by HPLC or mono-and bidimensional SDS-PAGE, followed ... using the well known EDMAN degradation method. ...
    Biology Products: